The mechanism of action suggested in APL and other studies is that miR-218 can inhibit BMI-1, which leads to an increase of p16INK4A to halt the cell cycle and p19ARF to inhibit p53 degradation [24,25,26]. Here, CDKN2A is linked to acute promyelocytic leukemia.